Table 2: Pre-treatment PSA level and examined proteins expression for two groups of patients having negative or positive clinical outcome after radical prostatectomy.
|
Characteristics |
Total Mean ± SE |
Seminal vesicle(s) invasion Mean (%) ± SE |
Radicality of surgery Mean (%) ± SE |
Positive surgical margin Mean (%) ± SE |
Local recurrence
Mean (%) ± SE |
Metastasis
Mean (%) ± SE |
|||||
|
N = 130 |
Negative N= 107 |
Positive N = 23 |
Negative N= 45 |
Positive N = 85 |
Negative N= 71 |
Positive N = 59 |
Negative N= 118 |
Positive N = 12 |
Negative N= 177 |
Positive N = 13 |
|
|
PSA ng/mL |
9.9 ± 0.5 |
9.4 ± 0.5 |
12.2± 1.6a |
11.7±1.1 |
8.9±0.5b |
9.0±0.5 |
10.9±0.9c |
9.8 ± 0.5 |
10.8 ± 1.0 |
9.7± 0.5 |
11.5 ± 1.2 |
|
Ki-67 LI (%)
|
8.1 ± 0.6 |
7.0 ± 0.6 |
12.9± 2.0d |
9.7±1.3 |
7.2±0.6e |
7.6±0.7 |
8.6±1.0 |
7.9 ± 0.6
|
9.6 ± 1.6 |
7.7 ± 0.6
|
11.7± 2.8f |
|
GLUT-1LI (%) |
30.4± 2.1 |
29.1± 2.2 |
36.0± 5.3 |
30.9±3.8 |
30.1±2.5 |
32.9±2.6 |
27.3±3.3 |
29.9± 2.2 |
35.1 ± 7.3 |
30.0± 2.2 |
33.5 ± 5.8
|
|
VEGF LI (%)
|
15.1± 1.4 |
14.9± 1.6 |
15.7± 2.8 |
13.7±1.8 |
15.8±1.9 |
15.5±2.0 |
14.6±2.0 |
15.3± 1.5 |
12.6 ± 3.6 |
15.5± 1.5 |
11.3 ± 2.8 |
|
MVD/mm2
|
97.1± 2.5 |
95.3± 2.6 |
105.4 ±6.6 |
92.2±3.2 |
99.7±3.2 |
102.7±3.5 |
90.3±3.3g |
97.0± 2.6 |
97.9 ± 9.1 |
97.5± 2.6 |
93.4 ± 6.1 |
|
PSMA LI (%)
|
44.6± 2.0 |
43.1± 2.2 |
51.7± 4.1 |
48.3±3.1 |
42.7±2.5 |
43.0±2.7 |
46.6±2.8 |
44.1± 2.0 |
50.3 ± 8.4 |
44.6± 2.0 |
45.2 ± 7.2 |
|
hTERT LI (%) |
56.5± 1.6 |
57.1± 2.9 |
53.5±5.3 |
53.3±4.6 |
58.2±3.0 |
62.1±3.4 |
49.7±3.7h |
56.5± 2.6 |
56.3 ± 9.3 |
58.5± 2.6 |
38.7 ± 7.9i |
ap = 0.025, bp = 0.006, c0.048, dp < 0.001, ep = 0.048, fp = 0.048, gp = 0.012, hp = 0.015, ip = 0.019. Differences between positive and negative subgroups (t-test).